Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its clinical development of LUCID-MS, a proprietary multiple sclerosis therapy candidate designed to target demyelination and protect or restore myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. This announcement is significant because multiple sclerosis affects approximately 2.8 million people worldwide, and current treatments primarily focus on modulating the immune system to reduce relapses, but do not directly repair myelin damage. LUCID-MS could potentially fill a critical gap in MS therapy by promoting remyelination and neuroprotection.
Quantum BioPharma is also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists. The company’s wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The advancement into Phase 2 trials represents a key milestone for the company and for the MS community, as it moves closer to a potential treatment that could alter the disease course.
To view the full article, visit https://ibn.fm/AUhNl. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.
